Pazopanib for the treatment of soft-tissue sarcoma

Figures & data

Table 1 Results of phase II trial

Strata	Response rate	Progression-free survival	Overall survival
Liposarcomas (n = 19)	0%	2.9 months	6.6 months
Leiomyosarcomas (n = 42)	2.4%	3.3 months	11.8 months
Synovial sarcomas (n = 38)	13.2%	5.8 months	10.3 months
Other sarcomas (n = 43)	7%	3.3 months	9.9 months

Table 2 Results of phase III trial

	Objective response	Stable disease	Progression-free survival	Overall survival
Pazopanib (n = 246)	9%	67%	4.6 months	12.5 months
Placebo (n = 123)	0%	38%	1.6 months	10.7 months

Table 3 Most frequent grade 3–4 adverse events

Most frequent grade 3–4 adverse events	Phase I trial (%)	Phase II trial (%)	Phase III trial (%)
Hypertension	25	7.7	7
Fatigue	2	7.7	13
Anorexia	0	–	6
Diarrhea	5	3.5	5
Thromboembolic event	6	0.007	3
Hyperbilirubinemia	2	6.3	–
Elevated transaminases	2	4.2	–
Proteinuria	3	0	–